Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study

被引:7
|
作者
Grymonprez, Maxim [1 ]
Petrovic, Mirko [2 ]
De Backer, Tine L. [3 ]
Steurbaut, Stephane [4 ,5 ]
Lahousse, Lies [1 ,6 ]
机构
[1] Univ Ghent, Fac Pharmaceut Sci, Dept Bioanal, Pharmaceut Care Unit, Ottergemsesteenweg 460, B-9000 Ghent, Belgium
[2] Ghent Univ Hosp, Dept Geriatr, C Heymanslaan 10, B-9000 Ghent, Belgium
[3] Ghent Univ Hosp, Dept Cardiol, C Heymanslaan 10, B-9000 Ghent, Belgium
[4] Vrije Univ Brussel, Ctr Pharmaceut Res, Res Grp Clin Pharmacol & Clin Pharm, Laarbeeklaan 103, B-1090 Jette, Belgium
[5] UZ Brussel, Dept Hosp Pharm, Laarbeeklaan 101, B-1090 Jette, Belgium
[6] Erasmus MC, Dept Epidemiol, POB 2040, NL-3000 CA Rotterdam, Netherlands
关键词
Atrial fibrillation; Frailty; Anticoagulant; Thromboembolism; Bleeding; Death; OLDER-ADULTS; WARFARIN; RIVAROXABAN; APIXABAN; DABIGATRAN; STATEMENT; OUTCOMES; INDEX; RISK;
D O I
10.1093/ehjqcco/qcad019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsData on non-vitamin K antagonist oral anticoagulants (NOACs) use in patients with atrial fibrillation (AF) and frailty are scarce. Therefore, the impact of frailty on AF-related outcomes and benefit-risk profiles of NOACs in patients with frailty were investigated.Methods and resultsAF patients initiating anticoagulation between 2013 and 2019 were included using Belgian nationwide data. Frailty was assessed with the Claims-based Frailty Indicator. Among 254 478 anticoagulated AF patients, 71 638 (28.2%) had frailty. Frailty was associated with higher all-cause mortality risks [adjusted hazard ratio (aHR) 1.48, 95% confidence interval (CI) (1.43-1.54)], but not with thromboembolism or bleeding. Among subjects with frailty (78 080 person-years of follow-up), NOACs were associated with lower risks of stroke or systemic embolism (stroke/SE) [aHR 0.77, 95%CI (0.70-0.86)], all-cause mortality [aHR 0.88, 95%CI (0.84-0.92)], and intracranial bleeding [aHR 0.78, 95%CI (0.66-0.91)], a similar major bleeding risk [aHR 1.01, 95%CI (0.93-1.09)], and higher gastrointestinal bleeding risk [aHR 1.19, 95%CI (1.06-1.33)] compared with VKAs. Major bleeding risks were lower with apixaban [aHR 0.84, 95%CI (0.76-0.93)], similar with edoxaban [aHR 0.91, 95%CI (0.73-1.14)], and higher with dabigatran [aHR 1.16, 95%CI (1.03-1.30)] and rivaroxaban [aHR 1.11, 95%CI (1.02-1.21)] compared with VKAs. Apixaban was associated with lower major bleeding risks compared with dabigatran [aHR 0.72, 95%CI (0.65-0.80)], rivaroxaban [aHR 0.78, 95%CI (0.72-0.84)] and edoxaban [aHR 0.74, 95%CI (0.65-0.84)], but mortality risk was higher compared with dabigatran and edoxaban.ConclusionFrailty was an independent risk factor of death. Non-vitamin K antagonist oral anticoagulants had better benefit-risk profiles than VKAs in patients with frailty, especially apixaban, followed by edoxaban. [GRAPHICS]
引用
收藏
页码:55 / 65
页数:11
相关论文
共 50 条
  • [1] Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy A Nationwide Cohort Study
    Jung, Hyunjean
    Yang, Pil-Sung
    Jang, Eunsun
    Yu, Hee Tae
    Kim, Tae-Hoon
    Uhm, Jae-Sun
    Kim, Jong-Youn
    Pak, Hui-Nam
    Lee, Moon-Hyoung
    Joung, Boyoung
    Lip, Gregory Y. H.
    [J]. CHEST, 2019, 155 (02) : 354 - 363
  • [2] Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with antiphospholipid syndrome: a nationwide cohort study
    Yang, P. S.
    Shim, M.
    Kang, S. H.
    Kim, S. H.
    Kim, W. J.
    Moon, J. Y.
    Sung, J. H.
    Kim, I. J.
    Lim, S. W.
    Cha, D. H.
    Lip, G. Y. H.
    Joung, B.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 : 656 - 656
  • [3] The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
    Grymonprez, Maxim
    Petrovic, Mirko
    De Backer, Tine L.
    Steurbaut, Stephane
    Lahousse, Lies
    [J]. THROMBOSIS AND HAEMOSTASIS, 2024, 124 (02) : 135 - 148
  • [4] Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
    Larsen, Torben Bjerregaard
    Skjoth, Flemming
    Nielsen, Peter Bronnum
    Kjaeldgaard, Jette Nordstrom
    Lip, Gregory Y. H.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2016, 353
  • [5] Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation
    Cha, Myung-Jin
    Choi, Eue-Keun
    Han, Kyung-Do
    Lee, So-Ryoung
    Lim, Woo-Hyun
    Oh, Seil
    Lip, Gregory Y. H.
    [J]. STROKE, 2017, 48 (11) : 3040 - +
  • [6] Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients
    Zhu, Wengen
    Ye, Zi
    Chen, Shilan
    Wu, Dexi
    He, Jiangui
    Dong, Yugang
    Lip, Gregory Y. H.
    Liu, Chen
    [J]. STROKE, 2021, 52 (04) : 1225 - 1233
  • [7] Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
    Nielsen, Peter Bronnum
    Skjoth, Flemming
    Sogaard, Mette
    Kjaeldgaard, Jette Nordstrom
    Lip, Gregory Y. H.
    Larsen, Torben Bjerregaard
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2017, 356
  • [8] Dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A Danish nationwide cohort study
    Xing, Lucas Yixi
    Barcella, Carlo Alberto
    Sindet-Pedersen, Caroline
    Bonde, Anders Nissen
    Gislason, Gunnar Hilmar
    Olesen, Jonas Bjerring
    [J]. THROMBOSIS RESEARCH, 2019, 178 : 101 - 109
  • [9] Safety and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Anemia: A Retrospective Cohort Study
    Wang, Chun-Li
    Wu, Victor Chien-Chia
    Huang, Yu-Tung
    Kuo, Chang-Fu
    Chu, Pao-Hsien
    Chen, Yu-Ling
    Wen, Ming-Shien
    Chang, Shang-Hung
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (09):
  • [10] Patients' experiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: A qualitative study
    Clarkesmith, Danielle E.
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    [J]. THROMBOSIS RESEARCH, 2017, 153 : 19 - 27